In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest

Applying Connectivity to Enhance The Training Standard of Care for Self-Injection
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Aptar Pharma expert Q&A on digital health and connected drug delivery
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Supporting Improved Patient Onboarding and Adherence with Training Solutions
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Enhancing The Patient Experience for Self-Injection Systems
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions